Phase II study of celecoxib in metastatic differentiated thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 6, 2006, Pages 2201-2204

  Mrozek, Ewa ^a,e   Kloos, Richard T ^b,c,e   Ringel, Matthew D ^a,b,d,e   Kresty, Laura ^a,e   Snider, Paulette ^a,e   Arbogast, Daria ^a,e   Kies, Merrill ^f   Munden, Reginald ^f   Busaidy, Naifa ^f   Klein, Mary Jean ^f   Sherman, Steven I ^f   Shah, Manisha H ^a,e,g  

^a Division of Hematology and Oncology   (United States)

^b Division of Endocrinology Metabolism and Diabetes

^c Division of Nuclear Medicine

^d Division of Human Cancer Genetics

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g A 438 Starling Loving Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOCALCEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEG CRAMP; LYMPHOCYTOPENIA; MALE; METASTASIS; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SYNCOPE; THYROID CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; SULFONAMIDES; THYROID NEOPLASMS;

EID: 33744961755     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2498     Document Type: Article

References (17)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83:2638-2648
2. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475-480
3. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C 1990 Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480-483
4. O'Doherty MJ, Coakley AJ 1998 Drug therapy alternatives in the treatment of thyroid cancer. Drugs 55:801-812
5. Schlumberger M, Baudin E, Travagli JP 1998 Papillary and follicular cancer of the thyroid. Presse Med 27:1479-1481
6. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160
7. Williams SD, Birch R, Einhorn LH 1986 Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer:ASoutheastern Cancer Study Group Trial. Cancer Treat Rep 70:405-407
8. Casey MB, Zhang S, Jin L, Kajita S, Lloyd RV 2004 Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocr Pathol 15:107-116
9. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey III TJ 2002 Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 87:358-363
10. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL 2002 Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 112:238-242
11. 2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. J Biol Chem 278:52131-52138
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
13. National Cancer Institute 1999 Common toxicity criteria, version 2.0. http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf
14. Sedghizadeh PP, Mallery SR, Thompson SJ, Kresty L, Beck FM, Parkinson EK, Biancamano J, Lang JC 2005 Expression of the serine protease DESC1 correlates directly with normal keratinocyte differentiation and inversely with head and neck squamous cell carcinoma progression. Head Neck 28:432-440
15. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M 2005 Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080
16. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B 2000 The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952
17. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ 2005 Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11:1999-2007